Literature DB >> 22237896

Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.

Gaby P Smits1, Pieter G van Gageldonk, Leo M Schouls, Fiona R M van der Klis, Guy A M Berbers.   

Abstract

Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of serum IgG antibodies against measles, mumps, rubella, and varicella-zoster virus (MMRV). However, this method is time- and material-consuming. Therefore, a multiplex immunoassay for the simultaneous quantitative detection of antibodies against MMRV was developed. In-house as well as commercially available antigens can be used, making the assay available for all laboratories. The multiplex assay is much more sensitive than the separate ELISAs and has a high specificity, and only 5 μl of serum is needed. Heterologous inhibition did not exceed 11.5%, while homologous inhibition varied between 91.3 and 97.9%. Good correlations with the in-house ELISAs for measles (R(2) = 0.98), mumps (R(2) = 0.97), and rubella (R(2) = 0.97) virus as well as with the ELISA kit for varicella-zoster virus (R(2) = 0.95) were obtained. In conclusion, the MMRV multiplex assay is a good alternative to the conventional ELISAs and suitable for use in serosurveillance and vaccine studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237896      PMCID: PMC3294611          DOI: 10.1128/CVI.05537-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  20 in total

1.  Prevalence of antibodies against rubella virus in The Netherlands 9 years after changing from selective to mass vaccination.

Authors:  R de Haas; S van den Hof; G A Berbers; H E de Melker; M A Conyn-van Spaendonck
Journal:  Epidemiol Infect       Date:  1999-10       Impact factor: 2.451

2.  Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides.

Authors:  Raymond E Biagini; Sonela A Schlottmann; Deborah L Sammons; Jerome P Smith; John C Snawder; Cynthia A F Striley; Barbara A MacKenzie; David N Weissman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

3.  Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps.

Authors:  T Harmsen; M C Jongerius; C W van der Zwan; A D Plantinga; C A Kraaijeveld; G A Berbers
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

4.  Immunosurveillance and the evaluation of national immunization programmes: a population-based approach.

Authors:  H E De Melker; M A Conyn-van Spaendonck
Journal:  Epidemiol Infect       Date:  1998-12       Impact factor: 2.451

5.  Antibodies against mumps in The Netherlands as assessed by indirect ELISA and virus neutralization assay.

Authors:  S van den Hof; M T A Beaumont; G A M Berbers; H E de Melker
Journal:  Epidemiol Infect       Date:  2003-08       Impact factor: 2.451

6.  Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage.

Authors:  S van den Hof; G A Berbers; H E de Melker; M A Conyn-van Spaendonck
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

7.  Measles outbreak in a community with very low vaccine coverage, the Netherlands.

Authors:  S van den Hof; C M Meffre; M A Conyn-van Spaendonck; F Woonink; H E de Melker; R S van Binnendijk
Journal:  Emerg Infect Dis       Date:  2001       Impact factor: 6.883

8.  Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions.

Authors:  J V Staros; R W Wright; D M Swingle
Journal:  Anal Biochem       Date:  1986-07       Impact factor: 3.365

9.  T cell immunity to measles viral proteins in infants and adults after measles immunization.

Authors:  Hayley A Gans; Linda L Yasukawa; Amanda Alderson; Mary Rinki; Ross Dehovitz; Yvonne Maldonado; Ann M Arvin
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

10.  Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Authors:  David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
View more
  30 in total

1.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

2.  Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens.

Authors:  Marta Vidal; Ruth Aguilar; Joseph J Campo; Carlota Dobaño
Journal:  J Immunol Methods       Date:  2018-01-31       Impact factor: 2.303

Review 3.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

4.  Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.

Authors:  Sandra Waaijenborg; Susan J M Hahné; Liesbeth Mollema; Gaby P Smits; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Jacco Wallinga
Journal:  J Infect Dis       Date:  2013-05-08       Impact factor: 5.226

5.  Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative.

Authors:  Myron M Levine; Marcela F Pasetti
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

6.  The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya.

Authors:  S Flasche; Imo Adetifa; C N Mburu; J Ojal; R Chebet; D Akech; B Karia; J Tuju; A Sigilai; K Abbas; M Jit; S Funk; G Smits; P G M van Gageldonk; F R M van der Klis; C Tabu; D J Nokes; Jag Scott
Journal:  BMC Med       Date:  2021-02-03       Impact factor: 8.775

7.  High risk of a large measles outbreak despite 30 years of measles vaccination in The Netherlands.

Authors:  L Mollema; G P Smits; G A Berbers; F R Van Der Klis; R S Van Binnendijk; H E De Melker; S J M Hahné
Journal:  Epidemiol Infect       Date:  2013-08-06       Impact factor: 4.434

Review 8.  Current perspectives in assessing humoral immunity after measles vaccination.

Authors:  Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2018-12-26       Impact factor: 5.683

9.  Dynamics of the serologic response in vaccinated and unvaccinated mumps cases during an epidemic.

Authors:  Patricia Kaaijk; Sigrid Gouma; Hinke I Hulscher; Wanda G Han; Deborah E Kleijne; Rob S van Binnendijk; Cécile A van Els
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks.

Authors:  Gaby Smits; Liesbeth Mollema; Susan Hahné; Hester de Melker; Irina Tcherniaeva; Sandra Waaijenborg; Rob van Binnendijk; Fiona van der Klis; Guy Berbers
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.